← Back to headlines
J&J Dips Despite Positive Outlook; AstraZeneca and Spero Secure China Deals
Johnson & Johnson's stock experienced a dip despite an upbeat outlook, while AstraZeneca and Spero Therapeutics announced new deals in China.
Sources
Showing 0 of 1 sources
No articles available in your preferred languages.
1 article available in other languages below.
Related Stories
Electricity Prices Expected to Rise Sharply in Finland This Autumn
9h ago
Economist Compares Investment Returns of Homeownership vs. Renting, Highlights Insurance Importance
9h ago
S&P 500 Firms Exceed EPS Estimates, Report Strong Profit Growth
9h ago
SBI Clerk Recruitment Opens for 1,538 Junior Associate Posts
9h ago